Live Breaking News & Updates on Johnson Lau|Page 9
Stay updated with breaking news from Johnson lau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin Athenex, Inc.February 18, 2021 GMT Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea. PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan, Singapore, and Malaysia Athenex’s Existing Partners Include Almirall, S.A., in the United States, Europe, and Russia; and Guangzhou Xiangxue Pharmaceutical in China Almirall launches Klisyri® for actinic keratosis in the U.S. today ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy . Athenex, Inc.February 11, 2021 GMT The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex, received FDA approval in December 2020 Across two large Phase III randomized controlled clinical trials (pooled data) [1], a short convenient five-day course of Klisyri® ointment resulted in a significantly higher proportion of patients with complete clearance of AK lesions at day 57 in the treated areas (49%) than with vehicle ointment (9%) ....
Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin) USA - English Artikel teilen ® (tirbanibulin) is a novel microtubule inhibitor, recently approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis (AK) of the face or scalp and is under evaluation by the European Medicines Agency (EMA) - ® (tirbanibulin) demonstrated complete clearance of AK lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle [i] Klisyri ® has a demonstrated safety profile with no patient withdrawals from the Phase III studies due to adverse events, and a once daily 5-day self-application period ....